Topics

Differences in Immunotherapy for CLL and Richter Transformation (RT)

Cancer Immunotherapy Tumor Microenvironment Chronic Inflammation Cellular Stress

Chronic lymphocytic leukemia and Richter transformation arise in the same clinical continuum but present different immunotherapy problems. CLL is an indolent B-cell malignancy with prolonged interaction between leukemia cells and a supportive lymphoid microenvironment. Richter transformation is an aggressive lymphoma, most often with diffuse large B-cell morphology, that develops in a subset of patients and can progress rapidly. Checkpoint blockade has generally shown limited activity in untransformed CLL, whereas selected Richter transformation cohorts have provided stronger evidence of responsiveness. This contrast reflects differences in tumor kinetics, antigenic context, checkpoint expression, and prior treatment rather than a simple change in histologic label, and it argues against extrapolating one immunotherapy result across both diseases Transformation may be clonally related or unrelated to the antecedent leukemia, adding another source of clinical and immunologic heterogeneity[1][2][3].

CLL drives broad immune dysfunction: T cells display chronic stimulation, altered synapse formation, inhibitory receptor expression, and impaired cytotoxicity, while nurse-like cells, stromal signals, and cytokines support malignant B-cell survival. Blocking PD-1 alone may therefore release only one restraint without restoring effective priming or effector fitness. Richter transformation can acquire additional genomic lesions, rapid proliferation, inflammatory signaling, and higher checkpoint-ligand activity, creating a biologically distinct target. Clonal relatedness to the preceding CLL also matters for prognosis and treatment response. In both settings, prior exposure to BTK or BCL2 pathway inhibitors can reshape disease and immunity, so the line of therapy influences how a checkpoint, bispecific antibody, or cellular product performs These differences affect both the probability of immune recognition and the capacity of endogenous T cells to execute a response[1][2].

Current immune applications include CD19-directed CAR-T cells, CD20×CD3 bispecific antibodies, and checkpoint-based combinations, with different expectations in CLL and Richter transformation. In CLL, reducing disease burden and improving T-cell fitness before collection may support cellular therapy, but heavily pretreated autologous cells can be difficult to manufacture and sustain. Richter transformation may require rapid bridging treatment because manufacturing delay is clinically consequential. Diagnostic biopsy is essential when transformation is suspected, since rising tumor burden or symptoms in CLL do not establish Richter disease and treatment differs substantially. Immune toxicity, infection, cytopenia, and hypogammaglobulinemia occur against a background of disease-related immune deficiency The practical contrast is tempo: CLL often permits biological optimization, whereas Richter transformation may not permit prolonged product development[1][3].

Future studies should stratify transformed disease by histology, clonal relationship, genomic features, checkpoint-ligand pattern, and prior targeted therapy. Serial lymph node and blood sampling can determine why circulating CLL and tissue-based Richter lesions respond differently. Rational combinations may pair BTK-pathway modulation with cellular or engager therapy, but sequence and immune effects need prospective testing. Off-the-shelf products could address urgent treatment timelines, whereas engineering that resists exhaustion may improve autologous CAR-T function in CLL. The critical principle is disease-specific immune design: CLL requires repair of a deeply dysfunctional host–leukemia ecosystem, while Richter transformation demands fast control of an aggressive lymphoma with its own antigenic and checkpoint biology Studies should report the untransformed and transformed compartments separately so that activity in one is not misread as control of both[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-10997 Ibrutinib
Ibrutinib (PCI-32765) is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
Btk   Ligands for Target Protein for PROTAC  
Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Non-Small Cell Lung Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
140
HY-L010 MAPK Compound Library
MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers. MCE designs a unique collection of 1,154 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Signaling Pathway Targeting Libraries

88
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L058 Glycolysis Compound Library
Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation. Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications. MCE provides a unique collection of 1,379 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Signaling Pathway Targeting Libraries

86
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L189 Amino Acid Metabolism Compound Library
Amino acids, as one of the most fundamental organic compounds in living organisms, serve not only as the basic building blocks of proteins but also but also undertake the functions of energy supply, neurotransmitter synthesis, and maintenance of internal environment stability.Amino acid metabolic enzymes are a class of enzymes involved in the metabolic processes of amino acids, catalyzing their synthesis, breakdown, transformation, and interactions with other metabolic pathways. Abnormalities in amino acid metabolic enzymes can lead to various metabolic diseases, such as phenylketonuria and hyperammonemia, etc. Therefore, actively exploring and regulating the processes of amino acid metabolism is crucial for the development of drugs related to these diseases. MCE designs a unique collection of 352 small molecules target amino acid metabolizing enzymes, which is an important tool for studying studying amino acid metabolism processes or metabolism-related drug development.
83
HY-L244 High-Efficiency Gene Editing Compound Library
In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies. To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 761 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

Signaling Pathway Targeting Libraries

83
HY-L247 Environmental Pollutant Compound Library
Environmental pollution refers to the process where human activities release harmful chemicals or energy (such as industrial waste, pesticides, and plastic particles) into the natural environment at a rate that exceeds the ecosystem's capacity for self-purification, leading to deterioration in the composition or state of the atmosphere, water bodies, and soil. Environmental pollution is not only a direct threat to biodiversity but also ultimately impacts human health through the bioaccumulation effect of the food chain. Therefore, the accurate identification and dynamic monitoring of pollutants constitute the scientific cornerstone for formulating environmental policies, assessing ecological risks, and promoting green chemistry transformation. MCE features a collection of 296 environmental pollutants, covering categories such as air pollutants, water pollutants, and pesticides, for research in the field of environmental chemistry.

Compound Characteristic Classified Libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-14650 DHEA
DHEA (Prasterone) is one of the most abundant steroid hormones. DHEA (Prasterone) mediates its action via multiple signaling pathways involving specific membrane receptors and via transformation into androgen and estrogen derivatives (e.g., androgens, estrogens, 7α and 7β DHEA, and 7α and 7β epiandrosterone derivatives) acting through their specific receptors.
Environmental Pollutants   Androgen Receptor   Endogenous Metabolite  
Digestive System Disease   Breast Cancer   Prostate Cancer   HIV Infection   Depression   Digestive System Inflammation   Cardiovascular Disease   SARS-CoV-2 Infection   Type 1 Diabetes   Crohn's Disease   Lupus Erythematosus   Osteoporosis  
61
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-17600 Acalabrutinib
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib can be used for CLL research. Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Btk  
Leukemia/Lymphoma/Myeloma   Digestive System Cancer   Metastatic Prostate Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
36
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-101474A Zanubrutinib
Zanubrutinib (BGB-3111) is a selective and orally active Bruton tyrosine kinase (Btk) inhibitor (IC50: 0.3 nM).
Btk  
Leukemia/Lymphoma/Myeloma   SARS-CoV-2 Infection   Rheumatoid Arthritis  
25
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-P9913A Rituximab (anti-CD20)
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

Species: Human

CD20  
Triple-Negative Breast Cancer   Acute Myeloid Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma   Multiple Myeloma   Multiple Sclerosis   Sickle Cell Disease   Rheumatoid Arthritis  
17
HY-P9913 Rituximab
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   CD20  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma   Systemic Lupus Erythematosus   Myasthenia gravis   Multiple Sclerosis   Rheumatoid Arthritis  
17
HY-N2329 Piperlongumine
Piperlongumine is a alkaloid, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome.
ERK   Reactive Oxygen Species (ROS)   Autophagy   Apoptosis   Bacterial   Ferroptosis  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Bacterial Infection   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis  
16
HY-19834 Fenebrutinib
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research.
Btk  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
12
HY-131328 Pirtobrutinib
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.
Btk  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
10
HY-109192 Tolebrutinib
Tolebrutinib (SAR442168) is an orally active, selective, and blood-brain barrier-penetrant BTK inhibitor with neuroactive properties. Tolebrutinib is being investigated for use in multiple sclerosis (MS), particularly secondary progressive multiple sclerosis (SPMS)..
Btk  
Experimental Autoimmune Encephalomyelitis   Multiple Sclerosis   Experimental Autoimmune Encephalomyelitis  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-N7038 Phytohemagglutinin
Phytohemagglutinin (PHA-M), the major seed lectin of the common bean, Phaseolus vulgaris, is a T-cell activator. Phytohemagglutinin stimulates human mononuclear leukocytes, inducing the expression of ChAT mRNA and potentiating ACh synthesis. Phytohemagglutinin induces dose- and time-dependent toxicity in THP-1 monocytes/macrophages, alters cellular morphology, causes organelle dysfunction, and increases the expression of NF-κB, COX2, IL-1β.
NF-κB   COX   Interleukin Related   Reactive Oxygen Species (ROS)  
Pancreatic Cancer   Depression   Pain   Autoimmune Disease   Digestive System Inflammation  
7
HY-128757 Remibrutinib
Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib has the potential for Chronic urticaria (CU) treatment.
Btk  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
6
HY-P9952 Belimumab
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research. The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.

Species: Human

TNF Receptor   CD20  
Blood Disease   Systemic Lupus Erythematosus   Myasthenia gravis   Rheumatoid Arthritis  
6
HY-153321 Bexobrutideg
Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker).
PROTACs   Btk  
Inflammation or Immune System Disease  
4
HY-126490 Phleomycin
Phleomycin is a copper-dependent DNA damaging agent and antibiotic with antitumor activity. Phleomycin binds to DNA and produces ROS in the presence of reducing agents (such as dithiothreitol and glutathione), inducing single-strand and double-strand breaks in DNA. Phleomycin can induce cell apoptosis or mutation and is widely used in cancer inhibition, microbial genetic transformation (as a screening marker to improve fungal transformation efficiency) and DNA repair mechanism research.

Source: Streptoalloteichus hindustanus

Bacterial   Antibiotic   DNA/RNA Synthesis  
Cancer   Bacterial Infection  
3
HY-112166 Rilzabrutinib
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM.
Btk  
Metabolic or Endocrine Disease   Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
3
HY-P9977 Amivantamab
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells.

Species: Human

EGFR  
Breast Cancer   Pancreatic Cancer   Ovarian Cancer   Non-Small Cell Lung Cancer  
3
HY-P9963 Blinatumomab
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.

Species: Human

CD19  
Cancer  
3
HY-P71140 S100A4 Protein, Human (C-His)
The S100A4 protein is a calcium-binding protein involved in angiogenesis, cell differentiation, apoptosis, and autophagy. S100A4 protein interacts with MYH9 to enhance cell motility and invasion. S100A4 also inhibits the pro-apoptotic function of TP53 by reducing its protein levels. S100A4 Protein, Human (C-His) is the recombinant human-derived S100A4 protein, expressed by E. coli , with C-6*His labeled tag.

Species: Human; Source: E. coli

3
HY-N6727 Gliotoxin
Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis. Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells. Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells.

Source: Aspergillus fumigatus

Apoptosis   PKA   NF-κB   Bacterial   Fungal   Antibiotic  
Cancer   Infection   Inflammation or Immune System Disease  
2
HY-P99711 Loncastuximab
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349).

Species: Human

CD19   ADC Antibodies  
Cancer  
2
HY-153220 Zelebrudomide
Zelebrudomide is an orally active BTK-targeting PROTAC degrader, with DC50 values of 4.5 nM and 31 nM against wild-type BTK and BTKC481S mutant, respectively. Zelebrudomide recruits the cereblon E3 ubiquitin ligase complex to mediate the degradation of BTK. Zelebrudomide also acts as a molecular glue to bind the cereblon E3 ubiquitin ligase complex, mediating the degradation of IKZF1 and IKZF3. Zelebrudomide can be used in the research of B-cell malignancies.
PROTACs   Btk  
Cancer  
2
HY-158105 ARV-393
ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon, induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma.
PROTACs   BCL6   CD20   IFNAR  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-P99507 Zenocutuzumab
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.

Species: Human

EGFR  
Breast Cancer  
2
HY-P99931 Epcoritamab
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.

Species: Human

CD3   CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-P9910 Obinutuzumab (FUT8-KO)
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

Species: Human

CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-W009884 Acetosyringone
Acetosyringone is a phenolic compound from wounded plant cells, enables virA gene which encodes a membrane-bound kinase to phosphorylate itself and activate the virG gene product, which stimulates the transcription of other vir genes and itself. Acetosyringone enhances efficient Dunaliella transformation of Agrobacterium strains.
Endogenous Metabolite  
2
HY-P71084 S100A4 Protein, Mouse (His)
The S100A4 protein, a calcium-binding protein, regulates cellular processes including motility, angiogenesis, differentiation, apoptosis, and autophagy.It interacts with MYH9 to enhance cell motility and chemotaxis.It modulates TP53 to reduce protein levels and stimulates cytokine production.S100A4 forms homodimers and interacts with PPFIBP1, ANXA2, TP53, CCR5, CXCR3, and FCGR3A, inhibiting FCGR3A phosphorylation.S100A4 Protein, Mouse (His) is the recombinant mouse-derived S100A4 protein, expressed by E.coli , with C-6*His labeled tag.

Species: Mouse; Source: E. coli

2
HY-N13015 Quercetin 5-O-β-D-glucopyranoside
Quercetin 5-O-β-D-glucopyranoside is a glycosylated flavonoid metabolite and flavonoid compound. Quercetin 5-O-β-D-glucopyranoside can be produced by microbial transformation of Quercetin (HY-18085) via Mucor hiemalis. Quercetin 5-O-β-D-glucopyranoside can be used in studies related to benign prostatic hyperplasia.

Source: Bombyx mori

Endogenous Metabolite  
Prostatic Hyperplasia  
1
HY-P2454 CSP1
CSP1 is a potent and selective ComD1 receptor agonist, with an IC50 of 10.3 nM. CSP1 is a major variants of competence-stimulating peptide (CSP), and it can regulate genetic transformation of S. pneumonia by modulating quorum sensing (QS). CSP1 can act as an antibacterial agent.
Bacterial  
Bacterial Infection  
1
HY-P99400 Samalizumab
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research.

Species: Human

Others  
Cancer  
1
HY-P99285 Denintuzumab
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.

Species: Human

ADC Antibodies   CD19  
Leukemia/Lymphoma/Myeloma  
1
HY-W286743 Nε-(Carboxymethyl)-L-lysine
Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of PLK1 and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties.
Polo-like Kinase (PLK)   ERK   NF-κB  
Liver Cancer  
1
HY-153084A CD19 CAR mRNA (Human)
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia.
mRNA   CD19  
Cancer  
1
HY-N0666S4 L-Aspartic acid-13C4
L-Aspartic acid-13C4 is the 13C-labeled L-Aspartic acid (HY-N0666). L-Aspartic acid is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid has no independent analgesic activity. L-Aspartic acid can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid promotes burst firing of central neurons. L-Aspartic acid can be used in studies related to cerebral ischemia and epilepsy.
Isotope-Labeled Compounds   iGluR   Biochemical Assay Reagents  
Epilepsy   Pain   Cerebrovascular Disease  
1
HY-P99272 Ulocuplumab
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.

Species: Human

CXCR  
Acute Myeloid Leukemia   Non-Hodgkin Lymphoma   Multiple Myeloma  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99113 Inebilizumab
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

Species: Human

ADC Antibodies   CD19  
Myasthenia gravis   Multiple Sclerosis  
1
HY-P99380 Zanidatamab
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity.

Species: Human

EGFR  
Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
1
HY-P99033 Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions.

Species: Human

CD20   CD3  
Cancer Immunology   Non-Hodgkin Lymphoma  
1
HY-P99024 Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Species: Human

CD20   CD3  
Cancer   Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-171191 REGN5093-M114
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528).
Antibody-Drug Conjugates (ADCs)   Microtubule/Tubulin   c-Met/HGFR  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-W757743 Acalabrutinib-d3
Acalabrutinib-d3 (ACP-196-d3) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).
Isotope-Labeled Compounds  
/
HY-P10793 Cyclic(YCDGFYACYMDV)
Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model.
EGFR   Apoptosis  
/
HY-113326 Phytoene
Phytoene (trans-Phytoene) is a carotene pigment. Phytoene is the precursor of all carotenoids. Phytoene is the predominant PT isomer in most carotenogenic organisms. Phytoene can delay the skin tumors appearance and reduce their number in mice that are induced the tumors with UV-B light. Phytoene leads to protection against oxidative stress and malignant transformation. Phytoene inhibits the proliferation of breast cancer cells.
Reactive Oxygen Species (ROS)  
/
HY-135146G GSK-3484862 (GMP)
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma.
DNA Methyltransferase   Apoptosis  
/
HY-P992178 ALLO-647
ALLO-647 is a human monoclonal antibody targeting CD52. ALLO-647 transiently and selectively depletes host lymphocytes to promote the proliferation of allogeneic CAR T-cell following infusion. ALLO-647 can be used for the research of B-cell lymphoma and follicular lymphoma.

Species: Human

NF-κB  
Leukemia/Lymphoma/Myeloma  
/
HY-P99442 Apolizumab
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro.

Species: Human

Apoptosis  
Cancer   Inflammation or Immune System Disease  
/
HY-13771S1 Ursodeoxycholic acid-13C
Ursodeoxycholic acid-13C is the 13C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active.
Isotope-Labeled Compounds   G protein-coupled Bile Acid Receptor 1   FXR   Endogenous Metabolite  
Cancer  
/
HY-10966G SB-590885 (GMP)
SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer.
Raf   Apoptosis  
Colorectal Cancer   Blood Disease  
/
HY-P991523 BI-836826
BI-836826 is a IgG1 chimerized and Fc-engineered anti-CD37 monoclonal antibody. BI 836826 displays both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic activities. BI-836826 can be used for the study of chronic lymphocytic leukemia.

Species: Human

Apoptosis  
Cancer  
/
HY-P11129 MAGE-A4 (286-294)
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
Others  
Cancer  
/
HY-P992439 PF-06747143
PF-06747143 is recombinant anti-human antibody targeting CXCR4. PF-06747143 blocks CXCL12-induced calcium flux, F-actin polymerization, chemotaxis, cell migration, and leukemic cell bone marrow homing. PF-06747143 reduces tumor burden and improves survival in mouse models of hematologic malignancies. PF-06747143 can be used for the research of chronic lymphocytic leukemia, acute myeloid leukemia, and hematologic malignancies.

Species: Human

CXCR  
Acute Myeloid Leukemia   Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Multiple Myeloma  
/
HY-P10851 HVEM(14-39)
HVEM(14-39) is a B- and T-lymphocyte attenuator (BTLA) peptide inhibitor. HVEM (14-39) can be combined with BTLA with a KD of 0.102 μM. HVEM(14-39) enhances the activation and proliferation of T cells by regulating the expression of BTLA and HVEM in T cells, and promotes the transformation of cells into effector memory T cells. HVEM(14-39) inhibits tumor cell proliferation and promotes late apoptosis. HVEM(14-39) has immunomodulatory effects and can be used in the study of cancer.
Apoptosis  
Inflammation or Immune System Disease  
/
HY-P991744 Anti-Mouse CXCR4 Antibody (Cx4Mab-1)
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma.
CXCR  
Chronic Lymphocytic Leukemia   Multiple Myeloma  
/
HY-N19313 Agelastatin D
Agelastatin D is a pyrrole-imidazole alkaloid and cytotoxic agent found in the Western Australian sponge Cymbastela sp.. Agelastatin D induces cytotoxic activity against cancer cells. Agelastatin D can be used for the research of chronic lymphocytic leukemia.

Source: Cymbastela sp.

Others  
Leukemia/Lymphoma/Myeloma  
/
HY-P991590 1D09C3
1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL).

Species: Human

MHC   Apoptosis   JNK   Reactive Oxygen Species (ROS)  
Cancer  
/
HY-12041G SP600125 (GMP)
SP600125 (GMP) is SP600125 (HY-12041) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis.
JNK   Autophagy   Apoptosis   Ferroptosis  
Bladder Cancer  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-107966 Heparin calcium (MW 15000-19000)
Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
Thrombin   Factor Xa   Autophagy   Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-N0444R Rubiadin (Standard)
Rubiadin (Standard) is the analytical standard of Rubiadin (HY-N0444). This product is intended for research and analytical applications. Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections.
Reference Standards   Fungal   HBV   Apoptosis   NF-κB   Reactive Oxygen Species (ROS)   Parasite   Bacterial  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-W728151 3-O-Caffeoylshikimic acid
3-O-Caffeoylshikimic acid is a caffeoylshikimic acid substance and phenolic acid that widely exists in the aerial parts of Equisetum arvense L. and Smilax glabra. During sulfur fumigation processing, 3-O-Caffeoylshikimic acid undergoes chemical transformation to produce 3-O-caffeoylshikimic acid sulfate and 3-O-caffeoylshikimic acid sulfite. At a high concentration (40 μM), 3-O-Caffeoylshikimic acid exhibits cytotoxic activity against human keratinocytes.
Drug Derivative  
/
HY-174353S CYP51-IN-23-d3
CYP51-IN-23-d3 is a potent and broad-spectrum CYP51 inhibitor with a MIC80 of 1 μg/mL against Aspergillus fumigatum. CYP51-IN-23-d3 can prevent fungal phase transformation and biofilm formation. CYP51-IN-23-d3 exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-23-d3 can be used for the study of invasive fungal infections (IFIs).
Isotope-Labeled Compounds   Cytochrome P450   Fungal  
Infection  
/
HY-W015824S6 L-Aspartic acid-13C-2
L-Aspartic acid-13C-2 is the 13C-labeled L-Aspartic acid (HY-N0666). L-Aspartic acid is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid has no independent analgesic activity. L-Aspartic acid can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid promotes burst firing of central neurons. L-Aspartic acid can be used in studies related to cerebral ischemia and epilepsy.
Isotope-Labeled Compounds   iGluR   Biochemical Assay Reagents  
Epilepsy   Pain   Cerebrovascular Disease  
/
HY-141901S1 DHEA-d5
DHEA-d5 (Prasterone-d5; Dehydroisoandrosterone-d5; Dehydroepiandrosterone-d5) is the deuterium labeled DHEA (HY-14650). DHEA (Prasterone) is one of the most abundant steroid hormones. DHEA (Prasterone) mediates its action via multiple signaling pathways involving specific membrane receptors and via transformation into androgen and estrogen derivatives (e.g., androgens, estrogens, 7α and 7β DHEA, and 7α and 7β epiandrosterone derivatives) acting through their specific receptors.
Isotope-Labeled Compounds   Androgen Receptor   Endogenous Metabolite  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-136441S Triclosan-methyl-d3
Triclosan-methyl-d3 is the deuterium labeled Triclosan-methyl. Triclosan-methyl is a transformation product of triclosan. Triclosan is a bactericide in personal care products such as toothpaste, shampoos, and soaps. Triclosan is also a stabilizing agent in a multitude of detergents and cosmetics.
Bacterial  
Infection  
/
HY-W011579 4-Benzoyl-3-methyl-1-phenyl-5-pyrazolone
4-Benzoyl-3-methyl-1-phenyl-5-pyrazolone, is a heterocyclic compound with a five-membered ring structure, which can be used as a starting material for organic synthesis, a reagent for organic transformation, and a biological probe for studying biological processes. 4-Benzoyl-3-methyl-1-phenyl-5-pyrazolone is a biomaterial or organic compound that can be used as a research-related biomaterial or organic compound in life sciences.
Biochemical Assay Reagents  
/
HY-122903S TK216-d4
TK216-d4 is the deuterium labeled TK216 (HY-122903). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. TK216 directly binds EWS-FLI1 and inhibits EWS-FLI1 protein interactions. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity.
Isotope-Labeled Compounds   DNA/RNA Synthesis  
/
HY-P10529 Ganglioside GM1-binding peptide p3
Ganglioside GM1-binding peptide p3 is a synthetic peptide that can specifically bind to the pentasaccharide part of GM1 ganglioside. The dynamic transformation of Ganglioside GM1-binding peptide p3 may play an important role in the function of GM1 as a multiple receptor, such as in the classical pathway of cholera toxin infection. Ganglioside GM1-binding peptide p3 can be used to study the interaction between GM1 and its ligands.
Trk Receptor  
Infection  
/
HY-P990870 Anti-CD19 Antibody (4G7)
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Mouse

CD19   IFNAR   Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P99825 Relfovetmab
Relfovetmab is a monoclonal antibody and also serves as a single-chain variable fragment component for engineering chimeric antigen receptors (CAR) in modified CAR-T cells. Relfovetmab can be used in studies of cancer and immune disorders.

Species: Feline

Others  
Cancer   Inflammation or Immune System Disease  
/
HY-N0666S L-Aspartic acid-13C
L-Aspartic acid-13C is the 13C-labeled L-Aspartic acid (HY-N0666). L-Aspartic acid is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid has no independent analgesic activity. L-Aspartic acid can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid promotes burst firing of central neurons. L-Aspartic acid can be used in studies related to cerebral ischemia and epilepsy.
Isotope-Labeled Compounds   iGluR   Biochemical Assay Reagents  
Epilepsy   Pain   Cerebrovascular Disease  
/
HY-P991224 CAP-100
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL.

Species: Human

CCR  
Cancer   Inflammation or Immune System Disease  
/
HY-P11056 REF1 peptide
REF1 peptide is a PORK1 agonist with an EC50 of 0.028 nM in tomato. REF1 peptide binds to the extracellular domain of PORK1, triggers receptor autophosphorylation, and drives downstream MPK3/MPK6 activation, thereby initiating defense and regeneration signaling cascades. REF1 peptide induces callus formation, inhibits shoot regeneration upon continuous exposure, and enhances the regeneration and transformation efficiency of recalcitrant dicotyledonous and monocotyledonous crops.
MDM-2/p53  
/
HY-P991226 RG7287
RG7287 is an activating antibody inhibitor targeting human CDCP1. RG7287 prevents the loss of contact inhibition caused by the co-transformation of NIH3T3 cells with CDCP1 and Src in focus formation assays. RG7287 inhibits tumor cell proliferation and leads to a significant reduction in CDCP1 levels.

Species: Human

Others  
Cancer  
/
HY-P99653A Ianalumab (FUT8-KO)
Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia.

Species: Human

TNF Receptor   Apoptosis   NF-κB  
Leukemia/Lymphoma/Myeloma   Autoimmune Disease  
/
HY-W010448 Imidazol-1-yl-acetic acid
Imidazol-1-yl-acetic acid is a BRS-3 agonist that mediates anorectic effects through activation of orphan G protein-coupled receptors (Orphan GPCR) in peripheral tissues; it also serves as a green, water-soluble, recyclable bifunctional organocatalyst for transformations such as Biginelli multicomponent reactions and epoxide ring opening. Imidazol-1-yl-acetic acid is used in the study of obesity.
Bombesin Receptor   Orphan GPCR  
Obesity  
/
HY-W075731 (Ir[dF(F)ppy]2(dCF3))PF6
(Ir[dF (F) ppy]2 (dCF3)) PF6 is a cyclometalated iridium (III) complex that is used in visible light-mediated photocatalytic organic transformations.
Biochemical Assay Reagents  
/
HY-N0444 Rubiadin
Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections.
Free Radical Scavengers   Reactive Oxygen Species (ROS)   NF-κB   HBV   Apoptosis   Bacterial   Fungal   Parasite  
Inflammation or Immune System Disease   Breast Cancer   Colorectal Cancer   Liver Cancer   Cervical Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Parasitic Infection   Epilepsy   Glucose Metabolism   Alzheimer's Disease   Liver Injury  
/
HY-107966A Heparin calcium (MW 3600-5000)
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
Thrombin   Factor Xa   Autophagy   Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-N0666S1 L-Aspartic acid-13C4,15N
L-Aspartic acid-13C4,15N is the 15N, 13C-labeled L-Aspartic acid (HY-N0666). L-Aspartic acid is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid has no independent analgesic activity. L-Aspartic acid can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid promotes burst firing of central neurons. L-Aspartic acid can be used in studies related to cerebral ischemia and epilepsy.
Isotope-Labeled Compounds   iGluR   Biochemical Assay Reagents  
Epilepsy   Pain   Cerebrovascular Disease  
/
HY-W012218 (±)-Camphor-10-sulfonic acid
(±)-Camphor-10-sulfonic acid is a racemate of Camphor-10-sulfonic acid. (±)-Camphor-10-sulfonic acid can be used as an organocatalyst in performing a huge array of organic transformations.
Biochemical Assay Reagents  
/
HY-N6744 Chaetoglobosin A
Chaetoglobosin A is a secondary metabolite and nematicide. Chaetoglobosin A is produced by Penicillium aquamarinium. Chaetoglobosin A targets Filamentous actin in cells, thereby inducing cell cycle arrest, and inhibiting membrane ruffle formation and cell migration. Chaetoglobosin A preferentially induces Apoptosis in chronic lymphocytic leukemia cells. Chaetoglobosin A induces dose- and time-dependent death in J2 larvae of the southern root-knot nematode (Meloidogyne incognita). Chaetoglobosin A can be used in studies related to root-knot nematode disease and chronic lymphocytic leukemia.

Source: Penicillium aquamarinium

Apoptosis   Endogenous Metabolite   Fungal   Parasite   Arp2/3 Complex  
Fungal Infection   Parasitic Infection   Chronic Myelogenous Leukemia  
/
HY-W034053 Ir[p-F(Me)ppy]2(dtbbpy)PF6
Ir[p-F (Me) ppy]2 (dtbbpy) PF6 is a cyclometalated iridium (III) complex. Ir[p-F (Me) ppy]2 (dtbbpy) PF6 absorbs visible light (460 nm) to form a long-lived charge-separated excited state. Ir[p-F (Me) ppy]2 (dtbbpy) PF6 is applicable to visible light-mediated photocatalytic organic transformation reactions.
Fluorescent Dye  
/
HY-N0881 Desacetylcinobufagin
Desacetylcinobufagin is a natural compound used for microbial transformation.

Source: toad

Others  
/
HY-W016813 trans-Aconitic acid
trans-Aconitic acid is an orally active aconitase inhibitor that non-competitively inhibits the conversion of citric acid to cis-aconitic acid and competitively inhibits the conversion of cis-aconitic acid to isocitric acid. trans-Aconitic acid inhibits the growth of Leishmania donovani promastigotes, the transformation of Leishmania donovani amastigotes to promastigotes, and the in vitro proliferation of Leishmania donovani amastigotes within macrophages in vitro. trans-Aconitic acid can be used in research related to visceral leishmaniasis (kala-azar).
Parasite  
Leishmania Infection  
/
HY-N0666S8 L-Aspartic acid-d3
L-Aspartic acid-d3 is the d3-labeled L-Aspartic acid (HY-N0666). L-Aspartic acid is a NMDA receptor agonist and acidic amino acid. L-Aspartic acid has no independent analgesic activity. L-Aspartic acid can antagonize the analgesic effects of D-Aspartic acid and Morphine. L-Aspartic acid regulates polymorph transformation, crystal growth/aggregation and nucleation processes of calcium carbonate, and can serve as a biomineralization template. L-Aspartic acid promotes burst firing of central neurons. L-Aspartic acid can be used in studies related to cerebral ischemia and epilepsy.
Isotope-Labeled Compounds   iGluR   Biochemical Assay Reagents  
Epilepsy   Pain   Cerebrovascular Disease  
/
HY-P99976 Anti-Mouse CD19 Antibody (1D3)
Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells.

Species: Mouse

CD19  
Inflammation or Immune System Disease  
/
HY-P99113A Inebilizumab (FUT8-KO)
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica.

Species: Human

CD19  
Multiple Sclerosis  
/
HY-172736 Toviblideg
Toviblideg (BMS-986458) is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. Toviblideg selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. Toviblideg modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of Toviblideg with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. Toviblideg induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma.
PROTACs   BCL6   CD20  
Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-P99868 Duvortuxizumab
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E.

Species: Human

CD19   CD3  
Cancer  
/
HY-P99761 Obexelimab
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus.

Species: Human

CD19   Apoptosis  
Inflammation or Immune System Disease  
/
HY-P9961 Ofatumumab
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL).

Species: Human

CD20  
Cancer  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P99392 Teclistamab
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).

Species: Human

CD3  
Cancer  
/
HY-P9999 Trontinemab
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1.

Species: Human

Amyloid-β  
Alzheimer's Disease  
/
HY-P71140A S100A4 Protein, Human (C/N-His)
The S100A4 protein is a calcium-binding protein involved in angiogenesis, cell differentiation, apoptosis, and autophagy. S100A4 protein interacts with MYH9 to enhance cell motility and invasion. S100A4 also inhibits the pro-apoptotic function of TP53 by reducing its protein levels. S100A4 Protein, Human (C/N-His) is the recombinant human-derived S100A4 protein, expressed by E. coli , with N-6*His, C-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P73734 p63/TP73L Protein, Human (sf9, His-GST)
The p63/TP73L protein is a sequence-specific DNA-binding transcriptional regulator that exhibits diverse activities through its isoforms. Isoform 2 activates RIPK4 transcription, and binding of this protein to TP73/p73 initiates p53/TP53-dependent apoptosis in response to genotoxic stress. p63/TP73L Protein, Human (sf9, His-GST) is the recombinant human-derived p63/TP73L protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P71191 PDCD4 Protein, Human (His)
PDCD4 inhibits translation initiation by disrupting the EIF4A1-EIF4G interaction and inhibiting EIF4A helicase activity. It regulates JUN kinase activation and downregulates MAP4K1, inhibiting invasion and tumorigenesis. PDCD4 Protein, Human (His) is the recombinant human-derived PDCD4 protein, expressed by E. coli , with C-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P701382 TRPA1 Protein, Human (HEK293, His, MBP, FLAG)
The TRPA1 protein is a receptor-activated nonselective cation channel that is critical for pain detection and may affect cold sensation, oxygen sensing, cough reflex, itch, and inner ear function. It responds to inflammatory mediators and irritants such as allyl thiocyanate (AITC), cinnamic aldehyde, diallyl disulfide (DADS), and acrolein. TRPA1 Protein, Human (HEK293, His, MBP, FLAG) is the recombinant human-derived TRPA1 protein, expressed by HEK293 , with N-10*His, N-MBP, C-Flag labeled tag.

Species: Human; Source: HEK293

/
HY-P80317 S100A4 Antibody (YA084)
S100A4 Antibody (YA084) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100A4.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P80269 PDCD4 Antibody (YA240)
PDCD4 Antibody (YA240) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDCD4.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81449 hnRNP K Antibody (YA1194)
hnRNP K Antibody (YA1194) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to hnRNP K.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86227 p63 Antibody (YA5919)
p63 Antibody (YA5919) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p63.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87520 PDCD4 Antibody (YA7204)
PDCD4 Antibody (YA7204) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDCD4.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P87967 hnRNP K Antibody (YA7652)
hnRNP K Antibody (YA7652) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to hnRNP K.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P811589 TRPA1 Antibody
TRPA1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to TRPA1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P81449A hnRNP K Antibody (YA1194)(PBS only)
hnRNP K Antibody (YA1194) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to hnRNP K.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83584 BNIP1 Antibody (YA3329)
BNIP1 Antibody (YA3329) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BNIP1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85626 S100A4 Antibody (YA5318)
S100A4 Antibody (YA5318) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to S100A4.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

Cell Biology Cell Culture Cell Transfection

/

Keywords

chronic lymphocytic leukemia | Richter transformation | immune checkpoint blockade | T-cell dysfunction | CAR-T cells | bispecific antibodies